Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00625898 · ClinicalTrials.gov registry record · Phase 3
BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab
A Phase 3 study, sponsored by NSABP Foundation.
- Terminated
- Registry status
- Phase 3
- Development phase
- 3,509
- Enrollment target
NCT00625898: Clinical Trial Phase 3 study, sponsored by NSABP Foundation.
NCT00625898 is a Phase 3 study that was terminated before completion, run by NSABP Foundation. The registered enrollment target is 3,509 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (355% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00625898, a Phase 3 study, was terminated before completion, sponsored by NSABP Foundation.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 3,509 participants
- Enrollment target
Study Summary
The trial will determine the value of adding bevacizumab to chemotherapy plus trastuzumab in patients with resected node-positive or high risk node-negative, HER2-positive breast cancer.
Interventions
- DRUG Trastuzumab
- DRUG Bevacizumab
- DRUG Carboplatin
- DRUG Docetaxel
- DRUG 5-Fluorouracil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,509 participants |
| Start Date | 2008-04 |
| Est. Completion | 2014-07 |
| Phase | Phase 3 |
Why NCT00625898 stopped before completion
NCT00625898 is an interventional study that assigns participants to a tested intervention. Its 3,509 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (355% higher).
The record links to 0 conditions, and to 5 interventions - of which Trastuzumab is the first listed.
NCT00625898 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00625898 about?
NCT00625898 is a clinical study titled "BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab". The trial will determine the value of adding bevacizumab to chemotherapy plus trastuzumab in patients with resected node-positive or high risk node-negative, HER2-positive breast cancer.
What is the current status of trial NCT00625898?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 3,509 participants. The study started on 2008-04. Estimated completion is 2014-07.
What interventions are being tested in trial NCT00625898?
The interventions under investigation include: Trastuzumab (DRUG), Bevacizumab (DRUG), Carboplatin (DRUG), Docetaxel (DRUG), 5-Fluorouracil (DRUG).
Who is sponsoring clinical trial NCT00625898?
This trial is sponsored by NSABP Foundation, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00625898's enrollment target sits among peer trials
3,509 68th of 2000 higher than 1,933 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00260559 · 3,500 participants
Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of Life
- NCT01612949 · 3,500 participants
Facial Analysis to Classify Difficult Intubation
- NCT02398786 · 3,500 participants
Myotonic Dystrophy Family Registry
- NCT03486873 · 3,500 participants · Phase 3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia